Your browser doesn't support javascript.
loading
Syk-dependent alternative homologous recombination activation promotes cancer resistance to DNA targeted therapy.
Zhou, Qin; Tu, Xinyi; Hou, Xiaonan; Yu, Jia; Zhao, Fei; Huang, Jinzhou; Kloeber, Jake; Olson, Anna; Gao, Ming; Luo, Kuntian; Zhu, Shouhai; Wu, Zheming; Zhang, Yong; Sun, Chenyu; Zeng, Xiangyu; Schoolmeester, Kenneth; Weroha, John; Wang, Liewei; Mutter, Robert; Lou, Zhenkun.
Affiliation
  • Zhou Q; Department of Radiation Oncology, Mayo Clinic.
  • Tu X; Department of Radiation Oncology, Mayo Clinic.
  • Hou X; Department of Oncology, Mayo Clinic.
  • Yu J; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic.
  • Zhao F; Department of Oncology, Mayo Clinic.
  • Huang J; Department of Oncology, Mayo Clinic.
  • Kloeber J; Department of Oncology, Mayo Clinic.
  • Olson A; Department of Oncology, Mayo Clinic.
  • Gao M; Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences.
  • Luo K; Department of Oncology, Mayo Clinic.
  • Zhu S; Department of Oncology, Mayo Clinic.
  • Wu Z; Department of Oncology, Mayo Clinic.
  • Zhang Y; Department of Oncology, Mayo Clinic.
  • Sun C; AMITA health saint joseph hospital.
  • Zeng X; Department of Oncology, Mayo Clinic.
  • Schoolmeester K; Laboratory Medicine and Pathology, Mayo Clinic.
  • Weroha J; Department of Oncology, Mayo Clinic.
  • Wang L; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic.
  • Mutter R; Department of Radiation Oncology, Mayo Clinic.
  • Lou Z; Department of Oncology, Mayo Clinic.
Res Sq ; 2023 Jun 09.
Article in En | MEDLINE | ID: mdl-37333340